A 5062 New Jersey General Assembly · 2026-2027 Regular Session

Requires health insurance and Medicaid coverage for testing and treatments to slow progression of Alzheimer's disease and related disorders.

This New Jersey bill mandates that health insurance plans and Medicaid cover medically necessary tests and FDA-approved treatments designed to slow the progression of Alzheimer's disease and related disorders. The law applies to hospital service, medical service, and health service corporation contracts, as well as individual and group health insurance policies issued or renewed in the state. A key provision ensures that these specific Alzheimer's treatments are not subject to step therapy requirements, meaning patients can access them without needing to try other medications first. Additionally, the coverage must be provided at the same level as benefits for other medical conditions.
Bill status passed 3 of 5 stages cleared
Introduction
May 2026
Committee Review
Jun 2026
General Assembly Passage
Jun 2026
Senate Passage
Governor
Introduced May 14, 2026 Last action Jun 30, 2026
Floor votes

How they voted

This bill passed the General Assembly by voice vote (no roll call recorded).
Full legislative history

Actions timeline

Total actions
4
Key actions
2
Committee
2
Jun 30, 2026
Lower · Passed
Passed by the Assembly (78-0-1)
lower
Jun 23, 2026
Lower · Passed
Reported out of Assembly Committee, 2nd Reading
lower
Jun 23, 2026
Committee
Transferred to Assembly Appropriations Committee
lower
May 14, 2026
Introduced
Introduced, Referred to Assembly Financial Institutions and Insurance Committee
lower
3 primary · 13 co-sponsors

Sponsors